AstraZeneca Pharma, Abbott Healthcare sign distribution pact for diabetes drug
Shares of AstraZeneca Pharma were trading 0.54 per cent higher at Rs 1,341.35 apiece on BSE.
- Country:
- India
Drug firm AstraZeneca Pharma India Friday said it has entered into a distribution agreement with Abbott Healthcare for distribution of diabetes medicine Dapagliflozin in India.
Dapagliflozin, an innovative Type 2 diabetes medicine, is AstraZeneca Pharma's leading diabetes medicine.
"Under the agreement, Abbott will promote and distribute Dapagliflozin under the brand name GLEDEPA. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name GLEDEPA MET," AstraZeneca Pharma said in a regulatory filing.
AstraZeneca Pharma, which did not share financial details of the agreement, said it will continue to promote and distribute dapagliflozin under the brand name Forxiga and combination of dapagliflozin with metformin under the brand name Xigduo.
Shares of AstraZeneca Pharma were trading 0.54 per cent higher at Rs 1,341.35 apiece on BSE.
(With inputs from agencies.)
- READ MORE ON:
- Merz Pharma GmbH & Co. KGaA
- Distribution
- Probability distribution
- Normal distribution
- Brand
- Corporate branding
- Co-branding
- Ibuprofen brand names
- Agreement
- Trade agreement
- Collective agreement
- AstraZeneca Pharma
- AstraZeneca Pharma India Friday
- Pharma
- Abbott Healthcare
- AstraZeneca
- Astra
- Zeneca
- Astra Zeneca
- Abbott
ALSO READ
FTSE 100 continues record run boosted by Anglo American, AstraZeneca
Clot in blood vessels occurs in rare cases with certain vaccines: Medical Expert amid reports over AstraZeneca
AstraZeneca reaffirms vaccine safety amidst rare side effect concerns
"Safety is primary focus for all our vaccines": Covaxin-developer Bharat Biotech amid reports on AstraZeneca vaccine
AstraZeneca acknowledges potential link between vaccine and rare blood clots in UK court